EVEREST MED (01952): Velsipity and Igar successfully included in the 2026 edition of the National Reimbursement Drug List

EVEREST MED (01952) announced that Velsipity (etrasimod arginine tablets) and Igar (eravacycline hydrochloride for injection) have passed the national medical insurance negotiation and been included for the first time in the new edition of the "National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026)" (the new edition of the National Reimbursement Drug List). This medical insurance inclusion will further enhance the accessibility and affordability of Velsipity and Igar, giving more patients the opportunity to benefit from innovative treatments. The new edition of the National Reimbursement Drug List will officially take effect on January 1, 2027. Meanwhile, Nefecon (budesonide enteric-coated capsules) will remain on the National Reimbursement Drug List. Velsipity (etrasimod arginine tablets) is China's first and only (as of November 2026) approved sphingosine-1-phosphate (S1P) receptor modulator for the treatment of ulcerative colitis (UC), administered as a once-daily oral dose. Its inclusion in the National Reimbursement Drug List adds a first-line guideline-recommended option for oral treatment of ulcerative colitis. Igar (eravacycline hydrochloride for injection) is the world's first and only (as of November 2026) fully synthetic fluorocycline antibacterial agent, used for the treatment of complicated intra-abdominal infections (cIAI) in adults, and is characterized by a broad antibacterial spectrum, strong antibacterial activity, confirmed clinical efficacy, and a favorable safety profile.